Psychedelics for Mental Illness: Dr. Joseph Varon on Trump’s Executive Order
In this episode, Fox News discusses President Trump's new executive order aimed at loosening restrictions and expanding access to psychedelic therapies for severe mental health conditions such as depression, PTSD, and addiction, especially among veterans. Dr. Joseph Varon, president and medical director of the Independent Medical Alliance, emphasizes that while the initiative holds promise, it must be pursued with rigorous scientific study and transparency to assess both benefits and risks. He notes that psychedelics are relatively inexpensive, which could allow broad treatment reach if proven effective, and argues that inaction would be the greater danger. The conversation highlights the need for prospective clinical trials to validate the hype surrounding these experimental drugs.
AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains
The episode recaps highlights from the AACR conference, emphasizing that AI is moving from pre‑clinical research into clinical oncology, but adoption is hampered by low digital pathology uptake (under 10% of U.S. labs), trust issues, and infrastructure costs. It then...
How AI and Robotics Designed New Cancer Therapies
In this episode, Angus Sinclair, CSO of LabGenius Therapeutics, explains how their AI‑driven AVA platform combines high‑throughput cell‑based assays with machine learning to design non‑intuitive protein therapeutics, specifically T‑cell engagers for solid tumors. He details the challenges of targeting antigens...
Scaling Bio 008: Serif Biomedicines' Jake Rubens on Turning Modified DNA Into a New Class of Medicine
In this episode, Jake Rubens of Serif Biomedicines explains how the company is turning DNA into a new class of medicines by using chemically modified DNA and a protein co‑factor to overcome DNA’s historic immunogenicity and delivery challenges. He contrasts...
Major Antineoplastic Mechanisms of Combination Ivermectin-Mebendazole
In this episode of American Sunrise, chief scientific officer Dr. Peter McCullough discusses a new wellness‑company study showing that the antiparasitic drugs ivermectin and mebendazole, when used alongside standard cancer therapies, yielded an 84% positive net clinical benefit in over 200...
The Real Drivers of GLP-1 Growth
In this episode, Terrence Flynn, Morgan Stanley’s Head of U.S. Pharma and Biotech Research, outlines the next phase of growth for GLP‑1 obesity medicines, estimating the market could peak at about $190 billion globally. He highlights five key drivers: the shift...
Rebuild, Don’t Just Relieve Pain: The Peptide Revolution for Lasting Joint Health
In this episode, host Steve discusses chronic inflammation and joint pain with Dr. Peter McCullough, chief scientific officer of a wellness company. Dr. McCullough explains how traditional pain relievers only mask symptoms, while their peptide‑based products—Regenerate (oral drops) and Therablu (topical...
DDW Highlights: 14 April 2026
In this episode, Bruno Quinney highlights three major developments: the discovery of a new recessive neurodevelopmental disorder linked to mutations in the non‑coding gene RNU4‑2, a first‑in‑human trial of personalized CAR‑T cell therapies for hard‑to‑treat solid tumors in children, and...
Can a Transplant Cure Aging? | Catherine Baucom MD PhD
In this episode, Dr. Robert Lovekin talks with Dr. Catherine Baucom, chief medical officer of MitoSense, and veteran health expert Van about mitochondrial organelle transplantation—a novel therapy that injects healthy mitochondria from young donors into patients to repair damaged cells....
The Psychedelic Revolution
The episode explores the emerging field of psychedelic therapy, highlighting its potential to treat treatment‑resistant mental health conditions with a few supervised dosing sessions rather than daily medication. Guests Dr. Will Vanderveer and Keith Kurlander explain how the approach combines...
One Reporter’s Life-Altering Psychedelic Trip
In this episode of The Daily, host Natalie Kittrow discusses ibogaine—a powerful, illegal psychedelic—with veteran New York Times reporter Robert Draper, who recounts his recent ten‑hour treatment in Tijuana, Mexico. Draper explains ibogaine’s origins, its potential to trigger neuroplasticity and...
Drugs From a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
In this episode of Touching Base, the GEN editors discuss how AI agents are accelerating scientific discovery, highlighting startups like Latent Labs that can design therapeutic antibodies from a simple text prompt and LabOS, an extended‑reality platform that integrates AI,...
Intercepting Cancer When DNA Surveillance Fails
In this episode, Daniel Levine talks with Marina Udier, CEO of Newscom, about the company’s innovative cancer‑interception strategy that targets tumors arising from microsatellite instability (MSI) and deficient DNA mismatch repair, such as those seen in Lynch syndrome. Udier explains...
DDW Highlights: 7 April 2026
In this episode, Bruno Quinney highlights several breakthrough developments in drug discovery: the FDA’s accelerated approval of Avlaya, the first brain‑penetrant biologic for Hunter syndrome; Eli Lilly’s $2 billion acquisition of Centessa Pharmaceuticals to expand its orexin‑based sleep‑wake therapies; Mount Sinai’s AI‑powered...
Decentralized Trials That Scale Globally Without Compliance Risks - with Emma Vitalini of Amgen
In this episode, Emma Vitalini, Head of Global Digital Health Technology Innovation at Amgen, discusses how AI and decentralized trial technologies are transforming patient recruitment, screening, and global trial accessibility. She explains that AI can rapidly parse unstructured genomic and...
209. Will Trump's Pharmaceutical Tariffs Lower Prices and Secure Supply Chains?
In this episode, host Chad Bowne and guest Tom Boyke dissect the Trump administration’s new pharmaceutical tariffs and the U.S.-U.K. pricing arrangement, explaining how they aim to address two distinct challenges: low‑margin generic drug shortages tied to China and India,...
Dr Sorcha O'Connor: The PsilOCD Study Investigating Low-Dose Psilocybin for OCD (#532)
In this episode, host Stuart Ralph talks with Dr. Saoirse O'Connor, a neuroscientist who led the PsilOCD study—the first controlled European trial of low‑dose psilocybin for obsessive‑compulsive disorder. The conversation covers the science of psilocybin, the study design (a 10 mg...
How Drug Discovery Is Tackling Global Health Challenges
In this DDW podcast episode, host Bruno Quinney discusses two recent DDW articles: one on the urgent need to combat antimicrobial resistance (AMR) with insights from Professor Janet Hemingway, and another on the rapid expansion of mRNA therapeutics. Hemingway highlights...
28 Months Later: FDA Still Hasn't Revealed Rick Bright and Janet Woodcock's Communications
The episode delves into the controversy surrounding the FDA’s handling of hydroxychloroquine during the COVID‑19 pandemic, focusing on whistleblower Dr. Rick Bright’s claims that Dr. Janet Woodcock pressured him to pursue an Emergency Use Authorization (EUA) rather than an expanded‑access protocol....
The War on Peptides — Why Retatrutide Is at the Center
In this episode of Business Game Changers, host Sarah Westall and Dr. Diane Kayser discuss the rapidly evolving peptide market, focusing on the upcoming weight‑loss peptide retatrutide (also called Reditrutide). They explain how big‑pharma is moving to control peptide supplements,...
Agentic AI, Virtual Cell, LNP Vaccine Boosters, Engineered Organs, and Mergers
In this episode of Touching Base, the Gen editorial team discusses the latest advances in AI for life sciences, including NVIDIA’s GTC announcements on agentic AI, the deployment of 3,500 GPUs by Roche, and the emergence of open‑source autonomous agents...
DDW Highlights: 26 March 2026
In this episode, Bruno Quinney highlights three breakthrough studies: Edinburgh researchers engineered E. coli to convert PET plastic waste into the Parkinson's drug L‑DOPA, offering a sustainable route to a vital medication; scientists identified the enzyme DHX8 as a key...
A Class Action Suits Moves RICO From Mobsters to Medicine
In this episode, attorney Harrison James explains how the Racketeer Influenced and Corrupt Organizations Act (RICO), originally aimed at organized crime, is being used in a landmark civil class action against Takeda Pharmaceuticals and Eli Lilly over the diabetes drug Actos....
Outsmarting Resistance with Rhythm
In this episode, Immuneering CEO Ben Zeskin explains the company’s novel “deep cyclic inhibition” dosing strategy, which delivers intense, short‑duration MEK inhibition pulses instead of continuous suppression. By restoring the natural intermittent signaling rhythm in healthy cells while repeatedly ambushing...
DDW Highlights: 17 March 2026
In this DDW Highlights episode, Bruno Quinney reviews four major stories: a Mayo Clinic study linking the Parkinson's protein alpha‑synuclein to dramatically faster Alzheimer’s progression in women; a Texas A&M‑funded project testing extracellular vesicle (EV) therapy to modulate microglia and...
#384 - Special Episode — Obicetrapib: The CETP Inhibitor with Cardiovascular Benefits and Potential Alzheimer's Prevention
In this special episode, host Peter Atiyah dives deep into obicetrapib, a CETP inhibitor that lowers LDL‑C and ApoB while raising HDL‑C, and examines its renewed promise in cardiovascular disease and potential Alzheimer’s prevention, especially for APOE‑E4 carriers. He outlines...
Editing Away Autoimmunity at the HLA Source
In this episode, Daniel Levine interviews Richard Freed, CEO of Rheumagen, about the pivotal role of HLA genes in autoimmune diseases and the company’s innovative gene‑editing approach to cure them. Freed explains how a single amino‑acid change at a conserved...
Gül Dölen – Psychedelic Science and Radical Healing
Gül Dölen, a leading neuroscientist at UC Berkeley and Johns Hopkins, discussed the transformative potential of psychedelic‑assisted therapy during the 2025 Aspen Ideas Festival. Her research demonstrates that compounds such as psilocybin and MDMA can rapidly alleviate treatment‑resistant depression, complex PTSD,...
Why Asia Is the Emerging Epicenter for Global Biopharmaceutical Progress
In this episode, Daniel Levine talks with Feng Nying Zhang, a partner at McKinsey Shanghai, about Asia’s rapid rise as a global hub for biopharmaceutical innovation, highlighted by a McKinsey report showing the region’s share of innovative drug pipelines jumping...
DDW Highlights: 3 March 2026
In this episode, Bruno Quinney highlights four major developments: a long‑acting injectable HIV regimen (cabotegravir + rilpivirine) that cut virological failure risk by nearly half versus daily oral therapy; SolasCure’s ORES wound gel, which accelerated debridement 22‑fold and healing seven‑fold in chronic...
🎧 What Investors Get Wrong About Hims & Hers, Ep. 2 with Paul Cerro
In this episode, the hosts dissect why investors misunderstand Hims & Hers' (HEMS) gross margin potential, emphasizing that as a compounder without its own API manufacturing, HEMS cannot achieve margins higher than drug manufacturers. They illustrate how HEMS' margin trajectory...
AI for Scientists, FDA Reverses Course, and Advances in Cancer Therapeutics
The episode covers three main business stories: Tamarin Bio’s $13.6M Series A to build an AI model‑coordination platform that makes tools like AlphaFold accessible to wet‑lab biologists; the FDA’s reversal on Moderna’s mRNA‑1010 seasonal flu vaccine, spurring a modest stock...
Drug Dealin Ep. 9: Using AI to Find Novel Treatment Options
In Episode 9 of Drug Dealin, hosts Kenny and Shibu demonstrate how patients can use publicly available tools like ClinicalTrials.gov and AI language models to uncover novel treatment options, focusing on a hypothetical Parkinson’s disease case inspired by a TV...
DDW Highlights: 17 February 2026
In this 16‑minute DDW Highlights episode, host Bruno Quinney recaps five major drug‑discovery stories from the past week, focusing on a breakthrough study linking specific biomarkers to improved cancer survival rates and the launch of a multinational consortium tackling chronic...
🎧 The GLP-1 Business Model Problem, Ep. 1 with Prof. Alex Miras
In the inaugural episode, host Alex discusses the GLP‑1 business model with obesity expert Prof. Alex Miras, who emphasizes that the drug itself drives the bulk of weight loss—about 20% versus 2.5% from behavioral support—making extensive multidisciplinary care unnecessary for...
DDW Highlights: 10 February 2026
In this 15‑minute episode, DDW host Bruno Quinney recaps five major stories from the past week, highlighting breakthrough cancer therapies that promise greater efficacy and safety, and new research aimed at enhancing brain function in Alzheimer’s patients. He also touches...